Tasly Pharmaceutical Group Co (SHSE:600535) 5-Year EBITDA Growth Rate : -17.20% (As of Mar. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Tasly Pharmaceutical Group Co 5-Year EBITDA Growth Rate?

Tasly Pharmaceutical Group Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.27.

During the past 12 months, Tasly Pharmaceutical Group Co's average EBITDA Per Share Growth Rate was 47.40% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -7.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -17.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Tasly Pharmaceutical Group Co was 33.00% per year. The lowest was -41.70% per year. And the median was 11.00% per year.

Competitive Comparison of Tasly Pharmaceutical Group Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tasly Pharmaceutical Group Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Tasly Pharmaceutical Group Co's 5-Year EBITDA Growth Rate falls into.

Tasly Pharmaceutical Group Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Tasly Pharmaceutical Group Co (SHSE:600535) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Tasly Pharmaceutical Group Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Tasly Pharmaceutical Group Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Tasly Pharmaceutical Group Co (SHSE:600535) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tasly Pharmaceutical Group Co Ltd (SHSE:600535) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

2 Pujihe Road East, Beichen District, Tasly TCM Garden, Tianjin, CHN, 300410

Website

http://www.tasly.com

Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.

Executives

Wu Nai Feng

Director

Tasly Pharmaceutical Group Co (SHSE:600535) Headlines

No Headlines